ArteraAI vs Nucs AI (2026)
Two companies working prostate cancer from different raw materials. ArteraAI builds multimodal tests combining image derived signal from tissue with clinical data, validated against treatment decisions, and reaching beyond one tumor type. Nucs works the imaging pathway, with products spanning automated analysis and the theranostics workflow around specialized prostate imaging. A prostate service could use both at different points, since one informs whether to treat more aggressively and the other supports how the disease is imaged and targeted. Neither carries a reviewed performance claim for its prognostic output, so the validation cohort is the thing to interrogate, particularly how well it matches your own population by stage, ancestry and treatment era.
- It builds multimodal cancer tests validated against treatment decisions, which is a different evidentiary object from a single slide model.
- The prognostic question sits inside a genuinely uncertain treatment decision, which is where a test can change management rather than confirm it.
- Breadth beyond one tumor type gives an oncology service more than one place to use it.
- It covers the prostate cancer pathway around specialized imaging, with products spanning automated analysis and the theranostics workflow.
- Depth in one disease across several products means the outputs connect rather than each standing alone.
- For a prostate service running specialized imaging, a pathway product fits how that service actually works.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. ArteraAI and Nucs AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
ArteraAI
-
Clinical evidence
Artera announced five ASTRO 2026 presentations on its multimodal AI prostate cancer biomarker.
Source -
Regulatory / guideline
The ArteraAI Prostate Test was included in the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer, making it the first AI enabled risk stratification tool recommended in those guidelines.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
ArteraAI is the Los Altos, California company at artera.ai that builds multimodal AI cancer tests. It is unrelated to Artera of Santa Barbara (artera.io), which makes patient communication agents.
Source: AI Health Index, August 2026
New York company, founded in 2024, building deep learning tools for PSMA PET/CT in prostate cancer and theranostics. DeepPSMA detects lesions, assigns TNM stage and quantifies whole body tumor burden; SelectPSMA predicts response to PSMA targeted radioligand therapy; TrackPSMA compares scans over time to evaluate treatment response.
Source: AI Health Index, August 2026
Questions buyers ask
How do ArteraAI and Nucs AI work with the EHR?
For ArteraAI, the authorized software takes images from FDA cleared scanners, which is scanner compatibility rather than record integration.
With Nucs AI, results come back as a structured, shareable report with staging, and research users can export structured data as CSV. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are ArteraAI and Nucs AI priced and sold?
In ArteraAI's case, the home page says the test is fully reimbursed for Medicare patients and that many commercial health plans cover it, and it links a billing page and a No Surprises Act notice.
For Nucs AI, the site addresses clinicians, biopharma teams, researchers and strategic partners. Access to DeepPSMA for investigational use is by request through a contact form, and the terms of service refer to a fee "if any" for platform access. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do ArteraAI and Nucs AI handle patient data?
With ArteraAI, the Notice of Privacy Practices sets out who receives health information and why, requires patient authorization for marketing or any sale, and gates research use behind an institutional review or privacy board. The security page states AES-256 encryption at rest and encryption in transit on AWS.
In Nucs AI's case, data is stored in encrypted form and access is limited to staff who need it, with an access log. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do ArteraAI and Nucs AI cover?
For ArteraAI, the authorized prostate software covers treatment naive core needle biopsies from men 55 and older without metastases who are candidates for curative treatment.
With Nucs AI, the products are investigational and not for clinical diagnostic use. Nothing published yet validates the stated coverage with counts: the accuracy figures come from internal studies with no populations described, and the any tracer claim has no results by tracer. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These serve the same cancer from different modalities, one from tissue and one from imaging, and a prostate service may use both at different decision points. Neither is a cleared device in the sense of a reviewed performance claim for the prognostic output, so the validation cohorts are what a buyer should interrogate, including how closely they match the local population by stage, ancestry and treatment era. Neither publishes pricing, a security attestation or a subgroup performance analysis.